Stealth Spins Out miRNA-Inhibition Technology Into New Company

Concurrent with the move, the new company has also secured an undisclosed amount of seed financing that is expected to enable the new firm to complete planned in vivo proof-of-concept studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.